Bayer/Onyx Nexavar Extends Life In Rare Thyroid Cancer

Regulatory filings will be based on results of the Phase III DECISION trial reported at ASCO showing a near double progression-free survival advantage compared to placebo; no further overall survival analyses will be done because of crossover.